UCLA researchers identify possible approach to prevent cancer from evolving to resist treatment

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

May 29, 2026

Vol.52 No.21

Cancer Policy

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants. The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Lab-grown organoids reveal how glioblastoma resists treatment

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy.

January 30, 2026

Vol.52 No.04

Clinical Roundup

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

January 30, 2026

Vol.52 No.04

UCLA researchers identify possible approach to prevent cancer from evolving to resist treatment

YOU MAY BE INTERESTED IN

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Lab-grown organoids reveal how glioblastoma resists treatment

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Renew today!

Subscriber content

Never miss an issue!

Login